在心力衰竭患者和保存的喷射小部分患者中使用介质素-6
Alessio Alogna1, Katlyn E Koepp2, Michael Sabbah2
1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA; Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany.
JACC. Heart failure
|August 11, 2023
概括
干白素-6 (IL-6) 在心力衰竭中升高,并与更差的运动能力和症状有关. 抑制IL-6可能会改善HFpEF患者的状态.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 内部医学 内部医学
背景情况:
- 洲际蛋白-6 (IL-6) 是一种关键的炎症调解剂,与心力衰竭 (HF) 有关.
- 在HF中记录了IL-6水平的升高,但特定于心力衰竭与保留射出分数 (HFpEF) 的数据有限.
研究的目的:
- 为了研究IL-6水平与心脏功能,拥堵,身体组成和高高压运动耐受性之间的关系.
- 了解IL-6在HFpEF群体中的临床影响.
主要方法:
- 分析了NHLBI赞助的四项试验中374名HFpEF患者的临床,实验室,身体组成和运动能力数据.
- 根据IL-6度的测量,患者被分为三层.
主要成果:
- 较高的IL-6水平与体重指数增加,炎症标志物 (NT-proBNP,CRP,TNF-α) 升高,功能较差和血红蛋白水平较低相关.
- 尽管静止心脏结构和功能相似,但具有最高IL-6的患者显著减少了峰值氧气消耗和6分钟的步行距离.
- IL-6与更大的身体脂肪,特别是干脂肪,在次最大运动期间增加症状,以及患者报告的健康状况下降有关.
结论:
- 升高的IL-6在HFpEF中很常见,并与更大的症状负担,运动能力降低和脂肪增加有关.
- 这些发现表明,IL-6抑制可能是改善HFpEF临床结果的潜在治疗策略.
相关概念视频
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:29Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
01:26Heart Failure III: Clinical Manifestations
23
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
23
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:30Heart Failure VII: Nursing Interventions
94
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
94
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13